A qualitative research exploring the experiences of patients receiving immune checkpoint inhibitors for advanced lung cancer

被引：0
作者：
Yunxia Hou
Yingge Hou
Jing Li
Lijuan Yu
Ling Yan
机构：
[1] Key Laboratory of Cancer Prevention and Therapy,Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer
[2] Tianjin Medical University,undefined
来源：
Supportive Care in Cancer | 2023年 / 31卷
关键词：
Immune checkpoint inhibitors; Stage IV non-small cell lung cancer; Quality of life; Qualitative research; Supportive care;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 271 条
  • [1] Chen W(2016)Cancer statistics in China, 2015 CA Cancer J Clin 66 115-132
  • [2] Zheng R(2022)Cancer statistics in China and United States, 2022: profiles, trends, and determinants Chin Med J 135 584-590
  • [3] Baade PD(2017)Precision diagnosis and treatment for advanced non-small-cell lung cancer N Engl J Med 377 849-861
  • [4] Zhang S(2014)Cancer statistics, 2014 CA Cancer J Clin 64 9-29
  • [5] Zeng H(2019)Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies Lung Cancer 135 188-195
  • [6] Bray F(2021)Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50 J Clin Oncol 39 2339-2349
  • [7] Jemal A(2017)Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial Lancet 389 255-265
  • [8] Yu XQ(2018)Immune-related adverse events associated with immune checkpoint blockade N Engl J Med 378 158-168
  • [9] He J(2020)Cancer patients’ experiences with immune checkpoint modulators: a qualitative study Cancer Med 9 3015-3022
  • [10] Xia C(2020)Immunotherapy and associated immune-related adverse events at a large UK centre: a mixed methods study BMC Cancer 20 743-376
12345678910